ZVIA vs. ASMB, TIL, VTVT, RLYB, PSNL, SLS, JAGX, CGTX, HOOK, and TKNO
Should you be buying Zevia PBC stock or one of its competitors? The main competitors of Zevia PBC include Assembly Biosciences (ASMB), Instil Bio (TIL), vTv Therapeutics (VTVT), Rallybio (RLYB), Personalis (PSNL), SELLAS Life Sciences Group (SLS), Jaguar Health (JAGX), Cognition Therapeutics (CGTX), Hookipa Pharma (HOOK), and Alpha Teknova (TKNO). These companies are all part of the "medical" sector.
Assembly Biosciences (NASDAQ:ASMB) and Zevia PBC (NYSE:ZVIA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, risk, profitability, media sentiment, valuation, dividends, institutional ownership, community ranking and analyst recommendations.
Assembly Biosciences has a beta of 0.6, indicating that its share price is 40% less volatile than the S&P 500. Comparatively, Zevia PBC has a beta of 0.66, indicating that its share price is 34% less volatile than the S&P 500.
Assembly Biosciences received 227 more outperform votes than Zevia PBC when rated by MarketBeat users. Likewise, 59.31% of users gave Assembly Biosciences an outperform vote while only 31.91% of users gave Zevia PBC an outperform vote.
Assembly Biosciences has a net margin of 0.00% compared to Assembly Biosciences' net margin of -15.58%. Assembly Biosciences' return on equity of -37.98% beat Zevia PBC's return on equity.
In the previous week, Assembly Biosciences had 6 more articles in the media than Zevia PBC. MarketBeat recorded 19 mentions for Assembly Biosciences and 13 mentions for Zevia PBC. Zevia PBC's average media sentiment score of 0.16 beat Assembly Biosciences' score of 0.08 indicating that Assembly Biosciences is being referred to more favorably in the media.
Zevia PBC has a consensus target price of $3.21, suggesting a potential upside of 199.84%. Given Assembly Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Zevia PBC is more favorable than Assembly Biosciences.
19.9% of Assembly Biosciences shares are owned by institutional investors. Comparatively, 53.2% of Zevia PBC shares are owned by institutional investors. 5.1% of Assembly Biosciences shares are owned by company insiders. Comparatively, 12.6% of Zevia PBC shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Zevia PBC has higher revenue and earnings than Assembly Biosciences.
Summary
Zevia PBC beats Assembly Biosciences on 10 of the 16 factors compared between the two stocks.
Get Zevia PBC News Delivered to You Automatically
Sign up to receive the latest news and ratings for ZVIA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ZVIA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Zevia PBC Competitors List
Related Companies and Tools
